



- (51) **International Patent Classification:**
C07D 413/10 (2006.01) *A61P 9/12* (2006.01)
A61K 31/4245 (2006.01)
- (21) **International Application Number:**
PCT/CN2013/070427
- (22) **International Filing Date:**
14 January 2013 (14.01.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
201210010823.3 14 January 2012 (14.01.2012) CN
- (71) **Applicants:** **SUNSHINE LAKE PHARMA CO., LTD.** [CN/CN]; Northern Industrial Area, Songshan Lake, Dongguan, Guangdong 523808 (CN). **RUYUAN HEC PHARM CO., LTD.** [CN/CN]; Rucheng Town, Ruayuan Yao Autonomous County, Guangdong 512721 (CN).
- (72) **Inventors:** **LEI, Xin**; Dongyangguang Hi-tech Park, No. 368 Zhen An Road, Shangsha, Chang An Town, Dongguan, Guangdong 523871 (CN). **LV, Zhiqing**; Dongyangguang Hi-tech Park, No. 368 Zhen An Road, Shangsha, Chang An Town, Dongguan, Guangdong 523871 (CN). **WANG, Tianming**; Dongyangguang Hi-tech Park, No. 368 Zhen An Road, Shangsha, Chang An Town, Dongguan, Guangdong 523871 (CN).

(74) **Agent:** **UNITALEN ATTORNEYS AT LAW**; 7th Floor, Scitech Place, No.22, Jian Guo Men Wai Ave., Chao Yang District, Beijing 100004 (CN).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** CRYSTALLINE FORMS OF AZILSARTAN MEDOXOMIL POTASSIUM AND PREPARATION AND USES THEREOF

(57) **Abstract:** The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan medoxomil potassium, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L. The substantially pure crystalline forms of azilsartan medoxomil potassium of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan medoxomil potassium generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan medoxomil potassium, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.




CRYSTALLINE FORMS OF AZILSARTAN MEDOXOMIL POTASSIUM AND PREPARATION AND USES THEREOF

TECHNICAL FIELD OF THE INVENTION


The present invention relates to the field of pharmaceutical chemistry. More particularly, the invention relates to novel crystalline forms of azilsartan medoxomil potassium, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.

BACKGROUND OF THE INVENTION

Azilsartan medoxomil, also known as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-2H-benzimidazole-7-carboxylate, having formula (I), is an angiotensin II antagonist prodrug of azilsartan (TAK-536), for the once-daily oral treatment of hypertension in adults, either alone or in combination with other antihypertensive agents,



Azilsartan medoxomil potassium salt has formula (II),



Azilsartan medoxomil potassium was first disclosed by Takeda in US 7157584, the method of preparation of azilsartan medoxomil potassium is disclosed in the specification of US 7157584, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate was dissolved in acetone, a solution of potassium 2-ethylhexanoate in acetone was added. The mixture was left standing overnight in a refrigerator, and the precipitated crystals were collected by filtration and dried under reduced pressure at room temperature to give azilsartan medoxomil potassium with a melting point of 196° C.

However, US 7157584 do not fully characterize the azilsartan medoxomil potassium polymorphs. Therefore, we do not know the polymorphic forms of the azilsartan medoxomil potassium disclosed in this reference.

A drug such as azilsartan medoxomil potassium may exist in different crystalline forms, which may have significant differences from each other in appearances, solubilities, melting points, dissolution rates, bioavailabilities, stability, efficacy and the like. Therefore, there is a need for novel crystalline forms of azilsartan medoxomil

potassium having better physicochemical properties, especially, relatively higher solubilities, bioavailabilities and/or efficacies. There is also a constant need for a low cost and industrial friendly process for preparing the crystalline forms of azilsartan medoxomil potassium.

DESCRIPTION OF THE INVENTION

As used herein, the term “crystalline form” of a compound refers to a unique ordered arrangement and/or conformations of molecules in the crystal lattice of the compound. As used herein, a crystalline form that is “substantially pure” refers to a crystalline form that is substantially free of one or more other crystalline forms, *i.e.*, the crystalline form has a purity of at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, or at least about 99.9%; or the crystalline form has less than 20%, less than 10%, less than 5%, less than 3%, less than 1%, less than 0.5%, less than 0.1%, or less than 0.01% of the one or more other crystalline forms, based on the total volume or weight of the crystalline form and the one or more other crystalline form.

As used herein, a crystalline form that is “substantially free” of one or more other crystalline forms refers to a crystalline form containing less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, or less than 0.01% of the one or more other crystalline form, based on the total volume or weight of the crystalline form and the one or more other crystalline form.

As used herein, an X-ray powder diffraction pattern that is “substantially as depicted” in a figure refers to an X-ray powder diffraction pattern having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of the peaks shown in the figure.

As used herein, the term “relative intensity” refers to the intensity of a peak with respect to the intensity of the strongest peak in the X-ray powder diffraction (XRPD) pattern which is regarded as 100%.

As used herein, the term “anti-solvent” refers to a solvent which can promote supersaturation and/or crystallization. In some embodiments, the solubility of azilsartan medoxomil potassium in the anti-solvent is less than 0.001 g/L, less than 0.01 g/L, less than 0.1 g/L, less than 0.2 g/L, less than 0.3 g/L, less than 0.4 g/L, less than 0.5 g/L, less than 0.6 g/L, less than 0.8 g/L, less than 1 g/L, less than 2 g/L, less than 3 g/L, less than 4 g/L, less than 5 g/L, less than 6 g/L, less than 7 g/L, less than 8 g/L, less than 9 g/L, or less than 10 g/L of the anti-solvent.

As used herein, the term “room temperature” refers to a temperature from about 18 °C to about 30 °C or a temperature from about 20 °C to about 24 °C or a temperature at about 22 °C.

As used herein, when referring to a spectrum and/or to data presented in a graph, the term “peak” refers to a feature that one skilled in the art would recognize as not attributable to background noise.

In the following description, all numbers disclosed herein are approximate values, regardless whether the word “about” is used in connection therewith. The value of each number may differ by 1%, 2%, 5%, 7%, 8%, 10%, 15% or 20%. Therefore, whenever a number having a value N is disclosed, any number having the value $N\pm 1\%$, $N\pm 2\%$, $N\pm 3\%$, $N\pm 5\%$, $N\pm 7\%$, $N\pm 8\%$, $N\pm 10\%$, $N\pm 15\%$ or $N\pm 20\%$ is specifically disclosed, wherein “ $\pm$ ” refers to plus or minus. Whenever a numerical range with a lower limit, RL, and an upper limit, RU, is disclosed, any number falling within the range is specifically disclosed. In particular, the following numbers within the range are specifically disclosed: $R = RL + k \cdot (RU - RL)$, wherein k is a variable ranging from 1% to 100% with a 1% increment, i.e., k is 1%, 2%, 3%, 4%, 5%, ..., 50%, 51%, 52%, ..., 95%, 96%, 97%, 98%, 99%, or 100%. Moreover, any numerical range defined by two R numbers as defined above is also specifically disclosed.

The present invention provides a novel crystalline form of azilsartan medoxomil potassium and its preparation thereof.

Provided herein are novel crystalline forms of azilsartan medoxomil potassium. The crystalline forms of a drug compound may have different chemical and physical properties, including melting point, chemical reactivity, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure and density. These properties can have a direct effect on the ability to process and/or manufacture the drug compound and the drug product, as well as on drug product stability, dissolution, and bioavailability. Thus the crystalline forms of azilsartan medoxomil potassium can affect the quality, safety, and efficacy of a drug product comprising azilsartan medoxomil potassium.

The principal embodiment of the present invention is to investigate whether azilsartan medoxomil potassium can exist in crystalline form. Unexpectedly, we have found that azilsartan medoxomil potassium can exist in many novel crystalline forms including form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L. In some embodiments, each of the novel crystalline form of azilsartan medoxomil potassium is substantially pure.

The crystalline forms of azilsartan medoxomil potassium may exhibit increased solubility and thermal stability; may provide better oral bioavailability and/or a better dissolution profile for a particular formulation; may also provide free-flowing easily filterable, and/or thermally stable characteristics that are suitable for use in particular formulations. The crystalline forms of azilsartan medoxomil potassium have low electrostatic property which is convenient to the operation of the production process. The crystalline forms of azilsartan medoxomil potassium may exhibit reducing clinical systolic blood pressure (SBP) and have a good performance in term of the 24-hour average clinical systolic. Therefore, they are suitable for preparing

pharmaceutical compositions for the prevention and/or treatment of hypertension. In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form A. In certain embodiments, form A of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form A has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 7.41 degree in term of two theta; In certain embodiments, form A has an X-ray powder diffraction pattern comprising one or more peaks at about 7.41, 22.83 degrees in term of two theta; In some embodiments, form A has an X-ray powder diffraction pattern comprising one or more peaks at about 7.41, 10.74, 18.19, 22.83, 23.29, 23.66 and 24.8 degrees in term of two theta; In certain embodiments, form A has an X-ray powder diffraction pattern comprising one or more peaks at about 4.50, 7.41, 8.97, 9.29, 10.74, 10.91, 12.54, 13.74, 14.55, 14.87, 15.52, 15.98, 16.49, 17.80, 18.19, 18.66, 18.90, 19.38, 19.74, 20.03, 20.57, 21.55, 21.91, 22.83, 23.29, 23.67, 24.20, 24.50, 24.80, 25.11, 25.63, 26.68, 27.30, 28.32, 28.77, 29.34, 29.95, 31.71 and 32.54 degrees in term of two theta; In certain embodiments, form A has an X-ray powder diffraction pattern substantially as depicted in Figure 1 wherein the peak at about 7.41 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form A can be detected, identified, classified and characterized using well-known techniques such as, but not limited to infrared (IR) spectroscopy, differential scanning calorimetry (DSC), form A melts at about 215.8 °C to about 222.4 °C by DSC analysis.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form B. In certain embodiments, form B of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form B has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 23.11 degree in term of two theta; In certain embodiment, form B has an X-ray powder diffraction pattern comprising one or more peaks at about 23.01, 23.11, 26.01, 28.32 degrees in term of two theta; In some embodiments, form B has an X-ray powder diffraction pattern comprising one or more peaks at about 5.79, 5.99, 15.56, 18.36, 20.07, 20.30, 20.93, 23.01, 23.11, 23.37, 25.24, 25.65, 26.01, 27.12, 28.32 degrees in term of two theta; In one embodiment, form B has an X-ray powder diffraction pattern comprising one or more peaks at about 5.79, 5.99, 11.54, 13.30, 14.68, 15.56, 16.31, 18.36, 20.07, 20.30, 20.66, 20.93, 21.08, 22.01, 22.40, 23.01, 23.11, 23.37, 25.24, 25.65, 26.01, 26.64, 27.12, 28.32, 29.53, 29.99, 32.98, 33.10, 36.48 degrees in term of two theta; In some embodiment, form B has an X-ray powder diffraction pattern substantially as depicted in Figure 2 wherein the peak at about 23.11 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form B can be detected, identified, classified and characterized using well-known techniques such as, but not limited to

infrared (IR) spectroscopy, DSC, form B melts at about 211.4 °C to about 218.8 °C by DSC analysis.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form C. In certain embodiments, form C of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form C has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 6.20 degree in term of two theta; In certain embodiment, form C has an X-ray powder diffraction pattern comprising one or more peaks at about 6.20, 18.70 degrees in term of two theta; In one embodiment, form C has an X-ray powder diffraction pattern comprising one or more peaks at about 6.20, 12.64, 13.36, 14.48, 16.00, 18.70, 20.30, 21.38, 22.78, 23.80, 25.04 degrees in term of two theta; In some embodiments, form C has an X-ray powder diffraction pattern comprising one or more peaks at about 6.20, 12.64, 13.36, 14.02, 14.48, 16.00, 17.74, 18.12, 18.70, 20.30, 21.38, 22.78, 23.80, 25.04, 25.60, 27.52, 28.16, 28.32, 31.32 degrees in term of two theta; In some embodiments, form C has an X-ray powder diffraction pattern substantially as depicted in Figure 3 wherein the peak at about 6.20 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form C can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR, DSC, in one embodiment, form C melts at about 212.8 °C to about 223.8 °C by DSC analysis; in some embodiments, form C melts at about 221.4 °C to about 223.8 °C by DSC analysis; in one embodiment, form C melts at about 218.3 °C to about 223.0 °C by DSC analysis; in one embodiment, form C melts at about 214.7 °C to about 221.3 °C by DSC analysis; in some embodiments, form C melts at about 217.2 °C to about 222.3 °C by DSC analysis; in certain embodiments, the IR spectrum of form C is substantially as depicted in Figure 4.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form D. In certain embodiments, form D of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form D has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 6.18 degree in term of two theta; In certain embodiment, form D has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 18.62 degrees in term of two theta; In one embodiment, form D has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 15.22, 18.62, 19.34, 23.54, 24.88, 26.94 degrees in term of two theta; In some embodiments, form D has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 12.14, 12.90, 14.26, 14.84, 15.22, 18.62, 19.34, 20.16, 21.62, 23.54, 24.88, 26.94 degrees in term of two theta; In certain embodiment, form D has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 12.14, 12.90, 13.64, 14.26, 14.84, 15.22, 17.38, 18.04,

18.62, 19.34, 20.16, 21.62, 22.30, 22.76, 23.54, 24.40, 24.88, 26.08, 26.94, 27.74, 31.56, 34.06; In some embodiments, form D has an X-ray powder diffraction pattern substantially as depicted in Figure 5 wherein the peak at about 6.18 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form D can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC, in one embodiment, form D melts at about 205.6 °C to about 220.1 °C by DSC analysis; in some embodiments, form D melts at about 206.6 °C to about 216.2 °C by DSC analysis; in one embodiment, form C melts at about 205.6 °C to about 216.7 °C by DSC analysis; in one embodiment, form D melts at about 214.8 °C to about 220.1 °C by DSC analysis; in one embodiment, form D melts at about 206.4 °C to about 214.3 °C by DSC analysis; in certain embodiments, the IR spectrum of form D is substantially as depicted in Figure 6.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form E. In certain embodiments, form E of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form E has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 6.16 degree in term of two theta; In certain embodiments, form E has an X-ray powder diffraction pattern comprising one or more peaks at about 6.16, 28.28 degrees in term of two theta; In some embodiments, form E has an X-ray powder diffraction pattern comprising one or more peaks at about 6.16, 13.34, 16.22, 18.58, 19.88, 21.46, 22.86, 26.84, 28.28, 33.62 degrees in term of two theta; In some embodiments, form E has an X-ray powder diffraction pattern substantially as depicted in Figure 7 wherein the peak at about 6.16 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form E can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC, form E melts at about 198.3 °C to about 208.4 °C by DSC analysis, in certain embodiments, the IR spectrum of form E is substantially as depicted in Figure 8.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form F. In certain embodiments, form F of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form F has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 17.96, 22.52, 23.32 degree in term of two theta; In one embodiment, form F has an X-ray powder diffraction pattern comprising one or more peaks at about 5.90, 8.46, 17.26, 17.96, 19.60, 21.66, 22.52, 23.32 degrees in term of two theta; In certain embodiments, form

F has an X-ray powder diffraction pattern substantially as depicted in Figure 9.

In certain embodiments, the characteristics of form F can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC, form F melts at about 94.2 °C to about 111.0 °C by DSC analysis; in certain embodiments, the IR spectrum of form D is substantially as depicted in Figure 10.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form G. In certain embodiments, form G of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form G has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 28.28 degree in term of two theta; In some embodiments, form G has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 28.28, 40.50 degrees in term of two theta; In certain embodiments, form G has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 13.32, 14.10, 14.44, 16.02, 17.80, 18.70, 21.30, 22.70, 22.90, 23.70, 24.38, 24.74, 26.90, 28.28, 40.50 degrees in term of two theta; In some embodiments, form G has an X-ray powder diffraction pattern substantially as depicted in Figure 11 wherein the peak at about 28.28 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form G can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form H. In certain embodiments, form H of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form H has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 6.18 degree in term of two theta; In some embodiments, form H has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 22.80 degrees in term of two theta; In certain embodiments, form H has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 13.32, 14.10, 14.36, 17.34, 18.72, 22.80, 23.56, 27.02 degrees in term of two theta; In some embodiments, form H has an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 12.08,

13.32, 14.10, 14.36, 15.14, 15.92, 17.34, 18.02, 18.72, 19.24, 20.18, 21.68,

22.80, 23.56, 24.96, 27.02, 27.60, 30.2; In some embodiments, form H has an X-ray powder diffraction pattern substantially as depicted in Figure 12 wherein the peak at about 6.18 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form H can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC, form H melts at about 213 °C to about 218 °C by DSC analysis.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form I. In certain embodiments, form I of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form I has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 6.06 degree in term of two theta; In some embodiments, form I has an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.10, 15.00, 19.54, 23.04 degrees in term of two theta; In certain embodiments, form I has an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.10, 13.86, 15.00, 18.72, 19.54, 21.54, 23.04, 23.88, 25.44, 28.36 degrees in term of two theta; In one embodiment, form I has an X-ray powder diffraction pattern substantially as depicted in Figure 13 wherein the peak at about 6.06 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form I can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form J. In certain embodiments, form J of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form J has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 13.18 degree in term of two theta; In some embodiments, form J has an X-ray powder diffraction pattern comprising one or more peaks at about 13.18, 23.24 degrees in term of two theta; In some embodiments, form J has an X-ray powder diffraction pattern comprising one or more peaks at about 13.18, 15.90, 20.18, 21.10, 22.22, 22.52, 23.24, 23.98 degrees in term of two theta; In certain embodiments, form J has an X-ray powder diffraction pattern comprising one or more peaks at about 5.94, 9.04, 9.94, 11.46, 11.88, 13.18, 14.26, 14.58, 15.90, 17.38, 17.80, 18.10, 19.32, 20.18, 21.10, 22.22, 22.52, 23.24, 23.98, 24.96, 26.44, 27.60, 28.30 degrees in term of two theta; In one embodiment, form J has an X-ray powder diffraction pattern substantially as depicted in Figure 14 wherein the peak at about 13.18 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form J can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form K. In certain embodiments, form K of azilsartan medoxomil

potassium disclosed herein is substantially pure. In some embodiments, form K has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 15.84 degree in term of two theta; In certain embodiments, form K has an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 13.22, 15.84, 20.14 degrees in term of two theta; In some embodiments, form K has an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.48, 13.22, 13.92, 14.34, 14.62, 15.84, 18.60, 20.14, 20.92, 22.66, 23.66, 24.00, 26.86 degrees in term of two theta; In one embodiment, form K has an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.48, 13.22, 13.92, 14.34, 14.62, 15.84, 17.62, 18.60, 19.36, 20.14, 20.92, 21.24, 22.66, 23.66, 24.00, 26.86, 27.40, 28.06, 29.04, 31.20, 32.88 degrees in term of two theta; In some embodiments, form K has an X-ray powder diffraction pattern substantially as depicted in Figure 15 wherein the peak at about 15.84 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form K can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC.

In some embodiments, the crystalline form of azilsartan medoxomil potassium is crystalline form L. In certain embodiments, form L of azilsartan medoxomil potassium disclosed herein is substantially pure. In some embodiments, form L has an X-ray powder diffraction pattern (XRPD) comprising a peak at about 20.92 degree in term of two theta; In certain embodiments, form L has an X-ray powder diffraction pattern comprising one or more peaks at about 10.34, 18.26, 20.92, 22.10, 24.06 degrees in term of two theta; In one embodiment, form L has an X-ray powder diffraction pattern comprising one or more peaks at about 10.34, 10.82, 14.52, 15.52, 17.52, 18.26, 19.00, 20.54, 20.92, 21.38, 22.10, 22.84, 23.48, 24.06, 24.36, 25.56 degrees in term of two theta; In certain embodiments, form L has an X-ray powder diffraction pattern comprising one or more peaks at about 7.48, 10.34, 10.82, 12.04, 13.10, 14.52, 15.52, 16.88, 17.52, 18.26, 19.00, 19.62, 20.54, 20.92, 21.38, 22.10, 22.84, 23.48, 24.06, 24.36, 25.56, 26.36 degrees in term of two theta; In certain embodiments, form L has an X-ray powder diffraction pattern substantially as depicted in Figure 16 wherein the peak at about 20.92 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

In certain embodiments, the characteristics of form L can be detected, identified, classified and characterized using well-known techniques such as, but not limited to IR、DSC.

According to the present invention, the X-ray powder diffraction was performed on the X-ray powder diffractometer model D/max-3A, data was collected over a 2 theta range of 3°-50°, scan rate 10°/min, using CuK.alpha radiation at a power of 25 mA and 35 kV. Wherein an ordinate or Y-axis is diffraction intensities in counts/second

(cps) and an abscissa or X-axis is the diffraction angle two theta in degrees.

The IR spectrum was detected on iS10; DSC thermograms were collected on a TA/Q2000 instrument, the samples were analyzed under a flow of nitrogen at a scan rate of 10 °C/minute, at Ramp 40-240°C.

It is worth noting that, for the X-ray powder diffraction peaks of a particular crystalline form, the two theta values may change slightly from one machine to another, from one sample to another. The difference in value may be about 1 degree, about 0.8 degrees, about 0.5 degrees, about 0.3 degrees, or about 0.1 degrees. Therefore, the above-mentioned values of two theta cannot be regarded as absolute.

The DSC thermograms may change slightly from one machine to another, and from one sample to another. The difference in value may be less than or equal to about 5 °C, or less than or equal to about 4 °C, or less than or equal to about 3 °C, or less than or equal to about 2 °C. Therefore, the melting points analysis by DSC given above cannot be regarded as absolute.

Also disclosed herein are two processes for preparing the crystalline forms A-L of azilsartan medoxomil potassium, wherein the processes comprise changing any one of the forms of azilsartan medoxomil potassium disclosed herein to another form of azilsartan medoxomil potassium. The crystalline forms of azilsartan medoxomil potassium salt obtained from the processes disclosed herein can be form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, and form L and wherein the novel crystalline form of azilsartan medoxomil potassium salt is substantially pure.

The first process for preparing the crystalline form of azilsartan medoxomil potassium salt disclosed herein comprising:

- a) adding azilsartan medoxomil to a solvent to form a mixture;
- b) heating the mixture or adding another solvent to form a solution;
- c) adding a solution of the potassium salt to the solution;
- d) forming crystals at a suitable temperature.

The azilsartan medoxomil can be prepared by using the process disclosed in US 7,157,584.

The mixture may be heated to a temperature sufficient to obtain complete solution or partial solution. The mixture may be heated to a temperature from about 40°C to the reflux temperature of the solution, or from about 55°C to about 65°C. In some embodiments, the mixture may be heated to a temperature at about 60 °C. In certain embodiments, the mixture may be heated to a reflux temperature.

The volume of solvent is from about 10 ml to about 300 ml per 1 g of azilsartan medoxomil. In some embodiments, the potassium salt is an organic acid potassium salt or an inorganic acid salt or a combination thereof. Some non-limiting examples of the inorganic acid salts include potassium nitrate, potassium sulfate, potassium sulfite, potassium bromate, potassium bicarbonate, potassium thiocyanate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate and combinations thereof. Some non-limiting examples of the organic acid salts include potassium hydrogen

phthalate, potassium acetate, potassium formate, potassium di-tert-butylphosphate, dipotassium glycyrrhizinate, potassium 2-ethylhexanoate, potassium ethyl xanthate, potassium sorbate and combinations thereof. The equivalent of potassium salt is from about 1.0 eq. to about 3.0 eq., or from about 1.0 eq. to about 2.0 eq., or from about 1.3 eq. to about 1.7 eq. with respect to azilsartan medoxomil.

The crystal was formed at a suitable temperature from about -20 °C to about 20 °C, or from about 0 °C to about 10 °C, or from about 0 °C to about 5 °C.

The second process for preparing the crystalline form of azilsartan medoxomil potassium comprising: adding azilsartan medoxomil potassium salt to a solvent or a mixture of solvent at a suitable temperature to form a solution, if necessary, adding another solvent to promote forming the solution; and forming crystals by cooling the solution.

In some embodiments, the suitable temperature is about 40 °C to a reflux temperature, the solution was then cooled to a temperature from about -20 °C to about 10 °C, or from about -10 °C to about 10°C, or from about 0 °C to about 5 °C. In some embodiments, the crystal was formed by cooling the solution then adding an anti-solvent to the solution.

In some embodiments, the solvent for process 1 and process 2 disclosed herein comprises one or more polar solvents, one or more non-polar solvents or a combination thereof. In certain embodiments, the solvent is dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), water, ether solvents, ketone solvents, ester solvents, aromatic hydrocarbon solvents, alkane solvents, nitrile solvents or combinations thereof. In other embodiments, the ether solvents are methyl tetrahydrofuran, tetrahydrofuran (THF), 1,4-dioxane, ethylene glycol dimethyl ether, methyl tert-butyl ether or a combination thereof. In some embodiments, the ketone solvents are acetone, butanone, or 4-methyl-2-pentanone or a combination thereof. In some embodiments the ester solvents are ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, sec-butyl acetate or a combination thereof; In some embodiments the hydrocarbon solvents are n-hexane, cyclohexane or n-pentane or n-heptane, toluene, xylene or a combination thereof; In some embodiments, halogenated solvents are dichloromethane (DCM), 1,2-dichloroethane, chloroform, carbon tetrachloride or a combination thereof; In some embodiments, nitrile solvents are acetonitrile (MeCN) or malononitrile or a combination thereof; In some embodiments, the nitro solvents are nitroethane, nitromethane, nitrobenzene or a combination thereof.

Provided herein is a process for preparing the crystalline form A of azilsartan medoxomil potassium salt comprising: adding azilsartan medoxomil to acetone; heating to reflux to form a solution; adding a solution of the potassium salt in acetone to the solution; then addition of acetic acid to attain a pH of 5-6, forming crystals at a suitable temperature.

Provided herein is a process for preparing the crystalline form B of azilsartan medoxomil potassium salt comprising: adding azilsartan medoxomil to acetone; heating to reflux to form a solution; adding a solution of the potassium salt in acetone

to the solution; forming crystals at a suitable temperature.

The process disclosed herein for preparing crystalline form C of azilsartan medoxomil potassium is substantially pure, wherein the solvent is propanone, 4-methyl-2-pentanone, ethyl acetate, dichloromethane, dichloroethane, iso-butyl acetate, sec-butyl acetate, methyl tetrahydrofuran, nitroethane, 1,2-dichloroethane, methyl ethyl ketone, 1,4-dioxane, ethylene glycol dimethyl ether, acetonitrile, tetrahydrofuran, cyclohexane or a combination thereof. In some embodiments, the solvent is a mixture of acetone and 1,4-dioxane, or a mixture of ethylene glycol dimethyl ether and acetonitrile, or a mixture of acetone and tetrahydrofuran, or a mixture of acetone and acetonitrile, or a mixture of acetone and sec-butyl acetate, or a mixture of tetrahydrofuran and dichloroethane, or a mixture of tetrahydrofuran and cyclohexane, or a mixture of acetone and dichloroethane, or a mixture of acetone and cyclohexane.

The process for preparing crystalline form D of azilsartan medoxomil potassium is substantially pure, wherein the solvent is selected from 1,4-dioxane, ethylene glycol dimethyl ether, acetonitrile, DMSO, acetone and combinations thereof. In some embodiment, the solvent is a mixed solvent of DMSO and acetone.

Also provided herein is a process for preparing crystalline form E of azilsartan medoxomil potassium, wherein the solvent is chloroform.

Also provided herein is a process for preparing crystalline form F of azilsartan medoxomil potassium, wherein the solvent is tert-butyl acetate or DMF and combinations thereof.

Also provided herein is a process for preparing crystalline form G of azilsartan medoxomil potassium, wherein the solvent is THF or carbon tetrachloride and combinations thereof.

Also provided herein is a process for preparing crystalline form H of azilsartan medoxomil potassium, wherein the solvent is ethylene glycol dimethylether, DMF, toluene, ethyl acetate, 1,4-dioxane, sec-butyl acetate or combinations thereof. In some embodiments, the solvent is a mixed solvent of ethylene glycol dimethyl ether, and DMF, or a mixed solvent of toluene and 1,4-dioxane, or a mixed solvent of ethyl acetate and 1,4-dioxane, or a mixed solvent of 1,4-dioxane and sec-butyl acetate.

Also provided herein is a process for preparing crystalline form I of azilsartan medoxomil potassium, wherein the solvent is acetonitrile or acetone and combinations thereof.

Also provided herein is a process for preparing crystalline form J of azilsartan medoxomil potassium, wherein the solvent is acetone, water, ethylene glycol dimethyl ether, tetrahydrofuran, DMSO, dichloromethane, acetonitrile, N-methyl pyrrolidone and combinations thereof. In some embodiments, the solvent is a mixed solvent of acetone and water; In some embodiments, the solvent is a mixed solvent of ethylene glycol dimethyl ether and tetrahydrofuran, or a mixed solvent of DMSO and dichloromethane, or a mixed solvent of acetone, ethylene glycol dimethyl ether and water, or a mixed solvent of acetonitrile and water, or a mixed solvent of acetonitrile, N-methylpyrrolidone and water.

Also provided herein is a process for preparing crystalline form K of azilsartan medoxomil potassium, wherein the solvent is acetonitrile.

Also provided herein is a process for preparing crystalline form L of azilsartan medoxomil potassium, wherein the solvent is tetrahydrofuran, water, NMP, DMF or 1,4-dioxane and combinations thereof. In some embodiments, the solvent is a mixed solvent of tetrahydrofuran and water, or a mixed solvent of tetrahydrofuran and NMP, or a mixed solvent of DMF and 1,4-dioxane.

The novel crystalline forms of azilsartan medoxomil potassium disclosed herein generally have good properties such as high solubility; thermal stability; better oral bioavailability; better dissolution profile for particular formulations; free-flowing; easily filterable; thermally stable which is suitable for particular formulations. The novel crystalline forms of azilsartan medoxomil potassium disclosed herein generally have good antistatic property which is convenient for operating the production process. The novel crystalline forms of azilsartan medoxomil potassium generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Therefore novel crystalline forms of azilsartan medoxomil potassium can be used for preparing a pharmaceutical composition for the prevention or treatment of hypertension.

In illustrative embodiments of the present invention, novel crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L of azilsartan medoxomil potassium is substantially pure, wherein the process for preparing the novel crystalline forms generally complies with the factory GMP production requirements, and is suitable for industrial production.

Also provided herein is a pharmaceutical composition comprising a therapeutically effective amount of a novel crystalline form disclosed herein such as form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L of azilsartan medoxomil potassium and one or more pharmaceutically acceptable carriers, excipients or diluents.

In certain embodiments, the pharmaceutical composition comprises crystalline forms of azilsartan medoxomil potassium, wherein the pharmaceutical compositions that are compacted into a dosage form, such as tablets, pills, powders and granules. The pharmaceutical compositions may include excipients or carriers, wherein the excipients or carriers comprise sodium citrate, calcium phosphate, fillers, binders, moisturizers, disintegrants, retarders, absorption enhancer, wetting agents, absorbents, lubricants and a combination thereof, wherein the fillers include starch, lactose, sucrose, glucose, mannitol, silicic acid and a combination thereof, wherein the binders include carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, gum Arabic and a combination thereof, wherein the moisturizers include glycerol, wherein the disintegrants include agar-agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates, and sodium carbonate, low substituted hydroxypropyl cellulose and a combination thereof; wherein the blockers solution include paraffin; wherein the absorption enhancer include quaternary ammonium

compounds; wherein the wetting agents include cetyl alcohol, monostearic acid glyceride and a combination thereof; wherein the absorbents include kaolin, bentonite and a combination thereof; wherein the lubricants include talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and a combination thereof.

The crystalline form of azilsartan medoxomil potassium disclosed herein or the pharmaceutical composition disclosed herein can be used in preventing or treating hypertension in a patient.

Also provided herein is a method of preventing or treating hypertension in a patient by administering to the patient a pharmaceutically effective amount of the crystalline form of azilsartan medoxomil potassium disclosed herein or the pharmaceutical composition disclosed herein.

Also provided herein is use of a pharmaceutical composition comprising a therapeutically effective amount of form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L of azilsartan medoxomil potassium and one or more pharmaceutically acceptable carriers, excipients or diluents to treat conditions in a subject in need thereof, such as a strong and long lasting angiotensin II antagonistic activity and hypotensive action, and an insulin sensitizing activity, and circulatory diseases such as hypertension, cardiac diseases (*e.g.* cardiac hypertrophy, cardiac failure, cardiac infarction).

DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the X-ray powder diffractogram of the crystalline form A of azilsartan medoxomil potassium.

Figure 2 depicts the X-ray powder diffractogram of the crystalline form B of azilsartan medoxomil potassium.

Figure 3 depicts the X-ray powder diffractogram of the crystalline form C of azilsartan medoxomil potassium.

Figure 4 depicts the infrared (IR) spectrum of the crystalline form C of azilsartan medoxomil potassium.

Figure 5 depicts the X-ray powder diffractogram of the crystalline form D of azilsartan medoxomil potassium.

Figure 6 depicts the infrared (IR) spectrum of the crystalline form D of azilsartan medoxomil potassium.

Figure 7 depicts the X-ray powder diffractogram of the crystalline form E of azilsartan medoxomil potassium.

Figure 8 depicts the infrared (IR) spectrum of the crystalline form E of azilsartan medoxomil potassium.

Figure 9 depicts the X-ray powder diffractogram of the crystalline form F of azilsartan medoxomil potassium.

Figure 10 depicts the infrared (IR) spectrum of the crystalline form F of azilsartan

medoxomil potassium.

Figure 11 depicts the X-ray powder diffractogram of the crystalline form G of azilsartan medoxomil potassium.

Figure 12 depicts the X-ray powder diffractogram of the crystalline form H of azilsartan medoxomil potassium.

Figure 13 depicts the X-ray powder diffractogram of the crystalline form I of azilsartan medoxomil potassium.

Figure 14 depicts the X-ray powder diffractogram of the crystalline form J of azilsartan medoxomil potassium.

Figure 15 depicts the X-ray powder diffractogram of the crystalline form K of azilsartan medoxomil potassium.

Figure 16 depicts the X-ray powder diffractogram of the crystalline form L of azilsartan medoxomil potassium.

EXAMPLES

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. Furthermore, numeric ranges are provided so that the range of values is recited in addition to the individual values within the recited range being specifically recited in the absence of the range.

Example 1

Preparation of crystalline form A of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in acetone (20 mL) at a reflux temperature to form a solution, the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.35 g) in acetone (1mL) was added slowly to the solution, the solution was slowly lowered to 0 °C, followed by addition of acetic acid drop-wise to attain a pH of 5-6, stirred for 5 hours at 0 °C and filtered, the solid was dried under vacuum at 45 °C for 12 hours to obtain white powder, the white powder was found to be crystalline form A of azilsartan medoxomil potassium having an XRPD as depicted in Figure 1.

Example 2

Preparation of crystalline form B of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in acetone (20 mL) at a reflux temperature to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.35 g) in acetone (1 mL) was added, the solution was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C and filtered, the solid was found to be crystalline form B of azilsartan medoxomil potassium having an XRPD as

depicted in Figure 2.

Example 3 to example 25 were the preparation of crystalline form C of azilsartan medoxomil potassium

Example 3

Azilsartan medoxomil (1.0 g) was dissolved in acetone (20 mL) at a reflux temperature to form a solution, after the solution was cooled to 50 °C, was added a solution of potassium 2-ethyl hexanoate (0.35 g) in acetone (1 mL), the solution was slowly lowered to 0 °C and stirred for 5 hours at 0 °C, then precipitated out, filtered, the solid was dried under vacuum at 45 °C for 12 hours to obtain white powder, the white powder was found to be crystalline form C of azilsartan medoxomil potassium having an XRPD as depicted in Figure 3.

Example 4

Azilsartan medoxomil (1.0 g) was dissolved in THF (20 mL) at a reflux temperature to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in THF (2 mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 5

Azilsartan medoxomil (1.0 g) was dissolved in 4-methyl-2-pentanone (80 mL) at a reflux temperature to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in 4-methyl-2-pentanone (2 mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 6

Azilsartan medoxomil (1.0 g) was dissolved in ethyl acetate (80 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl

hexanoate (0.5 g) in ethyl acetate (2 mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 7

Azilsartan medoxomil (1.0 g) was dissolved in acetone (80 ml) at 60 °C to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 8

Azilsartan medoxomil (1.0 g) was dissolved in DCM (100 ml) at 60 °C to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain a white powder, XRPD indicated that the white powder was form C of azilsartan medoxomil potassium.

Example 9

Azilsartan medoxomil (1.0 g) was dissolved in isobutyl acetate (90 ml) at 60 °C to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in isobutyl acetate (2mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that the white powder was form C of azilsartan medoxomil potassium.

Example 10

Azilsartan medoxomil (1.0 g) was dissolved in sec-butyl acetate (200 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in sec-butyl acetate (2mL) was added slowly to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that the white powder was form C of azilsartan medoxomil potassium.

Example 11

Azilsartan medoxomil (1.0 g) was dissolved in 2-methyltetrahydrofuran (90 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in 2-methyltetrahydrofuran (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that the white powder was form C of azilsartan medoxomil potassium.

Example 12

Azilsartan medoxomil (1.0 g) was dissolved in nitroethane (130 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in iso-butyl acetate (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that the white powder was form C of azilsartan medoxomil potassium.

Example 13

Azilsartan medoxomil (1.0 g) was dissolved in 1,2-dichloroethane (90 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C,

the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 14

Azilsartan medoxomil (1.0 g) was dissolved in butanone (25 ml) at 60 °C to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in butanone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 15

Azilsartan medoxomil (1.0 g) was added to sec-butyl acetate (15 ml) at 60 °C to form a mixture, to the mixture was added acetone (20 ml) to form a solution, the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone(2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 16

Azilsartan medoxomil (1.0 g) was added to 1,2-dichloroethane (15 ml) at 60 °C to form a mixture, to the mixture was added THF (15 ml) to form a solution, the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 17

Azilsartan medoxomil (1.0 g) was added to cyclohexane (20 ml) at 60 °C to form a

mixture, to the mixture was added THF (30 ml) to form a solution, the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in THF (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 18

Azilsartan medoxomil (1.0 g) was added to 1,2-dichloroethane (15 ml) at 60 °C to form a mixture, to the mixture was added acetone (15 ml) to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 19

Azilsartan medoxomil (1.0 g) was added to cyclohexane (20 ml) at 60°C to form a mixture, to the mixture was added acetone (25 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0°C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 20

Azilsartan medoxomil (1.0 g) was added to a mixed solvent of 1,4-dioxane (15 ml) and acetone (15 ml) at 60 °C to form a solution, after the solution was cooled to 50°C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone(2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0°C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of

azilsartan medoxomil potassium.

Example 21

Azilsartan medoxomil (1.0 g) was added to acetonitrile (15 ml) at 60 °C to form a mixture, to the mixture was added ethylene glycol dimethyl ether (15 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in ethylene glycol dimethyl ether (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 22

Azilsartan medoxomil (1.0 g) was added to a mixed solvent of acetone (15 ml) and THF (10 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 23

Azilsartan medoxomil (1.0 g) was added to acetonitrile (10 ml) at 60 °C to form a mixture, to the mixture was added acetone (15 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 24

Azilsartan medoxomil potassium (1.0 g) was added to acetone (300 ml), heating to reflux to form a solution, the solution was slowly lowered to 0 °C, further stirred for 5

hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 25

Azilsartan medoxomil potassium (1.0 g) was added to acetonitrile (200 ml) at 60 °C to form a solution, the solution was slowly lowered to 0 °C, stirred at 0 °C for 5 hours, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form C of azilsartan medoxomil potassium.

Example 26

Preparation of crystalline form D of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in 1,4-dioxane (20 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in 1,4-dioxane (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder which was found to be crystalline form D of azilsartan medoxomil potassium having an XRPD as depicted in Figure 5.

Example 27

Preparation of crystalline form D of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in ethylene glycol dimethyl ether (35 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in ethylene glycol dimethyl ether (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder which was found to be crystalline form D of azilsartan medoxomil potassium having an XRPD as depicted in Figure 5.

Example 28

Preparation of crystalline form D of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to acetone (60 ml) at to form a mixture, to the mixture was added DMSO (3 ml) to form a solution, the solution was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form D of azilsartan medoxomil potassium.

Example 29

Preparation of crystalline form E of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in chloroform (85 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder which was found to be crystalline form E of azilsartan medoxomil potassium having an XRPD as depicted in Figure 7.

Example 30

Preparation of crystalline form F of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in tert-butyl acetate (200 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in tert-butyl acetate (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder which was found to be crystalline form F of azilsartan medoxomil potassium having an XRPD as depicted in Figure 9.

Example 31

Preparation of crystalline form F of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to tert-butyl acetate (60 ml) at 60 °C to form a mixture, to the mixture was added DMF (3 ml) to form a solution, the solution was slowly lowered to 0 °C, followed by added water (100 ml), then precipitation out a white solid, further stirred for 5 hours at 0 °C, the solid was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white

powder, XRPD indicated that it was form F of azilsartan medoxomil potassium

Example 32

Preparation of crystalline form G of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was added to tetrachloromethane (15 ml) at 60 °C to form a mixture, to the mixture was added THF (18 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in THF (2mL) was added to the solution to form a reaction mixture which was slowly lowered to 0 °C, stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form G of azilsartan medoxomil potassium.

Example 33

Preparation of crystalline form H of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was added to toluene (15 ml) at to form a mixture, to the mixture was added 1,4-dioxane (30 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in 1,4-dioxane (2 mL) was added to the solution to form a reaction mixture which was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form H of azilsartan medoxomil potassium.

Example 34

Preparation of crystalline form H of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was added to ethyl acetate (15 ml) at to form a mixture, to the mixture was added 1,4-dioxane (20 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in 1,4-dioxane (2 mL) was added to the solution to form a reaction mixture which was slowly lowered to 0°C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form H of azilsartan medoxomil potassium.

Example 35

Preparation of crystalline form H of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was added to sec-butyl acetate (15 ml) at to form a mixture, to the mixture was added 1,4-dioxane (15 ml) to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in 1,4-dioxane (2 mL) was added to the solution to form a reaction mixture which was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form H of azilsartan medoxomil potassium.

Example 36

Preparation of crystalline form H of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to ethylene glycol dimethyl ether (40 ml) at to form a mixture, to the mixture was added DMF (10 ml) to form a solution, after the solution was cooled to 20 °C, crystalline out, the mixture was further stirred for 5 hours at 20 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form H of azilsartan medoxomil potassium.

Example 37

Preparation of crystalline form I of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was dissolved in acetonitrile (90 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in acetone (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder which was found to be crystalline form I of azilsartan medoxomil potassium having an XRPD as depicted in Figure 13.

Example 38

Preparation of crystalline form J of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to acetone (40 ml) at to form a mixture, to the mixture was added water (1 ml) to form a solution, the solution was cooled to 50 °C, to the solution was added water (100 ml) to form a mixture, the mixture was slowly lowered to 0 °C, keeping stirring for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white

powder, XRPD indicated that it was form J of azilsartan medoxomil potassium.

Example 39

Preparation of crystalline form J of azilsartan medoxomil potassium

Azilsartan medoxomil (1.0 g) was added to a mixed solvent of ethylene glycol dimethyl ether (15 ml) and THF (15 ml) at 60 °C to form a solution, after the solution was cooled to 50 °C, a solution of potassium 2-ethyl hexanoate (0.5 g) in THF (2 mL) was added to the solution to form a reaction mixture, the reaction mixture was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder which was found to be crystalline form J of azilsartan medoxomil potassium having an XRPD as depicted in Figure 14.

Example 40

Preparation of crystalline form J of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to DCM (60 ml) at 60 °C to form a mixture, to the mixture was added DMSO (4 ml) to form a solution, the solution was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form J of azilsartan medoxomil potassium.

Example 41

Preparation of crystalline form J of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to acetone (40 ml) at 60 °C to form a mixture, to the mixture was added a mixed solvent of ethylene glycol dimethyl ether (20 ml) and water (4 ml) to form a solution, the solution was slowly lowered to 0 °C, further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form J of azilsartan medoxomil potassium.

Example 42

Preparation of crystalline form J of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to acetonitrile (40 ml) at 60 °C to

form a mixture, to the mixture was added water (1 ml) to form a solution, after the solution was slowly lowered to 0 °C, was added water (60 ml), the above mixture was further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form J of azilsartan medoxomil potassium.

Example 43

Preparation of crystalline form J of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to acetonitrile (40 ml) at 60 °C to form a mixture, to the mixture was added NMP (20 ml) to form a solution, the solution was cooled to 0 °C, followed by added water (120 ml) which was further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form J of azilsartan medoxomil potassium.

Example 44

Preparation of crystalline form K of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to acetonitrile (100 ml) at 60 °C to form a solution, the solution was slowly lowered to 0 °C, then was further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form K of azilsartan medoxomil potassium.

Example 45

Preparation of crystalline form L of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to THF (20 ml) at to form a mixture, to the mixture was added water (1 ml) to form a solution, the solution was cooled to 50 °C, followed by added water (150 ml) which was slowly lowered to 0 °C and stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form L of azilsartan medoxomil potassium.

Example 46

Preparation of crystalline form L of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to THF (60 ml) at 60 °C to form a mixture, to the mixture was added NMP (3 ml) to form a solution, after the solution was slowly cooled to 0 °C, was added water (100 ml), then crystalline out, the mixture was further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form L of azilsartan medoxomil potassium.

Example 47 Preparation of crystalline form L of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to 1,4-dioxane (50 ml) at to form a mixture, to the mixture was added DMF (10 ml) to form a solution, the solution was cooled to 0 °C and was added water (50 ml) to form a mixture, the mixture was further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form L of azilsartan medoxomil potassium.

Example 48

Preparation of crystalline form L of azilsartan medoxomil potassium

Azilsartan medoxomil potassium (1.0 g) was added to THF (40 ml) at to form a mixture, to the mixture was added a mixed solvent of ethylene glycol dimethyl ether (20 ml) and water (1 ml) to form a solution, after the solution was slowly cooled to 0 °C, was added water (100 ml) which was further stirred for 5 hours at 0 °C, the crystal was collected by filtration, dried under vacuum at 45 °C for 12 hours to obtain white powder, XRPD indicated that it was form L of azilsartan medoxomil potassium.

Example 49

Stability Test

The stability test of the crystalline form C was conducted under the following conditions:

Storage condition 1: stored under conditions of 40°C./RH75% in a sealed state for 3 and 6 months. As a result, conversion of the crystalline form C into other polymorphs could not be confirmed after six months under the storage condition 1. During the whole test period, no change in total amount of impurities was recognized as compared with that before the beginning of the test.

Storage condition 2: stored under conditions of 40°C./RH75% in an unsealed state for 1 and 3 months.

As a result, conversion of the crystalline form C into other polymorphs could not be

confirmed after three months under the storage condition 2 but the total amount of impurities increased as compared with that before the beginning of the test.

Example 50

Solubility test

The crystalline form C, D, F, H, J and L of azilsartan medoxomil potassium (0.50 g) was added to the solvent at room temperature. The solid was dissolved by shaking for 30 seconds every 5 minutes and then the solubility of the solid was observed with eyes. The solid was deemed as dissolved when no solid was detected in the mixture by human eyes.

The solubility data of crystalline forms C, D, F, H, J and L of azilsartan medoxomil potassium are as shown below.

	Methanol	Ethanol	Acetone	THF	Ethyl acetate	Result
Form C	5 ml	6 ml	8 ml	13 ml	10 ml	dissolved
Form D	4 ml	5 ml	9 ml	16.5 ml	12 ml	dissolved
Form F	4.5 ml	6 ml	12 ml	15 ml	16 ml	dissolved
Form H	6 ml	8 ml	10 ml	14 ml	13 ml	dissolved
Form J	4 ml	5.5 ml	8 ml	12 ml	11 ml	dissolved
Form L	5 ml	6 ml	11 ml	17 ml	14 ml	dissolved

Example 51

A tablet contains crystalline form A of azilsartan medoxomil potassium, comprising: crystalline form A of azilsartan medoxomil potassium, mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate.

Example 52

A tablet contains crystalline form B of azilsartan medoxomil potassium, comprising: crystalline form B of azilsartan medoxomil potassium, mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate.

Example 53

A tablet contains crystalline form C of azilsartan medoxomil potassium comprising: crystalline form C of azilsartan medoxomil potassium, mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate.

Example 54

A tablet contains crystalline form D of azilsartan medoxomil potassium comprising:

crystalline form D of azilsartan medoxomil potassium, mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate.

Example 55

A tablet contains crystalline form H of azilsartan medoxomil potassium, comprising: crystalline form H of azilsartan medoxomil potassium, mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate.

Example 56

A tablet contains crystalline form L of azilsartan medoxomil potassium, comprising: crystalline form L of azilsartan medoxomil potassium, mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate.

CLAIMS

1. A crystalline form of azilsartan medoxomil potassium, wherein the crystalline form is form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L and wherein the crystalline form of azilsartan medoxomil potassium is substantially pure.
2. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form A, wherein form A has an X-ray powder diffraction pattern comprising a peak at about 7.41 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 7.41, 22.83 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 7.41, 10.74, 18.19, 22.83, 23.29, 23.66 and 24.80 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 4.50, 7.41, 8.97, 9.29, 10.74, 10.91, 12.54, 13.74, 14.55, 14.87, 15.52, 15.98, 16.49, 17.80, 18.19, 18.66, 18.90, 19.38, 19.74, 20.03, 20.57, 21.55, 21.91, 22.83, 23.29, 23.67, 24.20, 24.50, 24.80, 25.11, 25.63, 26.68, 27.30, 28.32, 28.77, 29.34, 29.95, 31.71 and 32.54 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 1 wherein the peak at about 7.41 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.
3. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form B, wherein form B has an X-ray powder diffraction pattern comprising a peak at about 23.11 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 23.01, 23.11, 26.01, 28.32 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 5.79, 5.99, 15.56, 18.36, 20.07, 20.30, 20.93, 23.01, 23.11, 23.37, 25.24, 25.65, 26.01, 27.12, 28.32 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 5.79, 5.99, 11.54, 13.30, 14.68, 15.56, 16.31, 18.36, 20.07, 20.30, 20.66, 20.93, 21.08, 22.01, 22.40, 23.01, 23.11, 23.37, 25.24, 25.65, 26.01, 26.64, 27.12, 28.32, 29.53, 29.99, 32.98, 33.10, 36.48 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 2 wherein the peak at about 23.11 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.
4. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form C, wherein form C has an X-ray powder diffraction pattern comprising a peak at about 6.20 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.20, 18.70 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.20, 12.64, 13.36, 14.48, 16.00, 18.70, 20.30, 21.38,

22.78, 23.80, 25.04 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.20, 12.64, 13.36, 14.02, 14.48, 16.00, 17.74, 18.12, 18.70, 20.30, 21.38, 22.78, 23.80, 25.04, 25.60, 27.52, 28.16, 28.32, 31.32 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 3 wherein the peak at about 6.20 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

5. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form D, wherein form D has an X-ray powder diffraction pattern comprising a peak at about 6.18 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 18.62 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 15.22, 18.62, 19.34, 23.54, 24.88, 26.94 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 12.14, 12.90, 14.26, 14.84, 15.22, 18.62, 19.34, 20.16, 21.62, 23.54, 24.88, 26.94 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 12.14, 12.90, 13.64, 14.26, 14.84, 15.22, 17.38, 18.04, 18.62, 19.34, 20.16, 21.62, 22.30, 22.76, 23.54, 24.40, 24.88, 26.08, 26.94, 27.74, 31.56, 34.06 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 5 wherein the peak at about 6.18 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

6. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form E, wherein form E has an X-ray powder diffraction pattern comprising a peak at about 6.16 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.16, 28.28 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.16, 13.34, 16.22, 18.58, 19.88, 21.46, 22.86, 26.84, 28.28, 33.62 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 7 wherein the peak at about 6.16 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

7. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form F, wherein form F has an X-ray powder diffraction pattern comprising a peak at about 17.96, 22.52, 23.32 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 5.90, 8.46, 17.26, 17.96, 19.60, 21.66, 22.52, 23.32 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 9 .

8. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form G, wherein form G has an X-ray powder diffraction pattern

comprising a peak at about 28.28 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 28.28, 40.50 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 13.32, 14.10, 14.44, 16.02, 17.80, 18.70, 21.30, 22.70, 22.90, 23.70, 24.38, 24.74, 26.90, 28.28, 40.50 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 11 wherein the peak at about 28.28 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

9. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form H, wherein form H has an X-ray powder diffraction pattern comprising a peak at about 6.18 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 22.80 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 13.32, 14.10, 14.36, 17.34, 18.72, 22.80, 23.56, 27.02 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.18, 12.08, 13.32, 14.10, 14.36, 15.14, 15.92, 17.34, 18.02, 18.72, 19.24, 20.18, 21.68, 22.80, 23.56, 24.96, 27.02, 27.60, 30.2 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 12 wherein the peak at about 6.18 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

10. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form I, wherein form I has an X-ray powder diffraction pattern comprising a peak at about 6.06 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.10, 15.00, 19.54, 23.04 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.10, 13.86, 15.00, 18.72, 19.54, 21.54, 23.04, 23.88, 25.44, 28.36 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 13 wherein the peak at about 6.06 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

11. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form J, wherein form J has an X-ray powder diffraction pattern comprising a peak at about 13.18 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 13.18, 23.24 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 13.18, 15.90, 20.18, 21.10, 22.22, 22.52, 23.24, 23.98 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 5.94, 9.04, 9.94, 11.46, 11.88, 13.18, 14.26, 14.58, 15.90, 17.38, 17.80, 18.10,

19.32, 20.18, 21.10, 22.22, 22.52, 23.24, 23.98, 24.96, 26.44, 27.60, 28.30 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 14 wherein the peak at about 13.18 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

12. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form K, wherein form K has an X-ray powder diffraction pattern comprising a peak at about 15.84 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 13.22, 15.84, 20.14 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.48, 13.22, 13.92, 14.34, 14.62, 15.84, 18.60, 20.14, 20.92, 22.66, 23.66, 24.00, 26.86 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 6.06, 12.48, 13.22, 13.92, 14.34, 14.62, 15.84, 17.62, 18.60, 19.36, 20.14, 20.92, 21.24, 22.66, 23.66, 24.00, 26.86, 27.40, 28.06, 29.04, 31.20, 32.88 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 15 wherein the peak at about 15.84 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

13. The crystalline form of azilsartan medoxomil potassium of claim 1, wherein the crystalline form is form L, wherein form L has an X-ray powder diffraction pattern comprising a peak at about 20.92 degree in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 10.34, 18.26, 20.92, 22.10, 24.06 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 10.34, 10.82, 14.52, 15.52, 17.52, 18.26, 19.00, 20.54, 20.92, 21.38, 22.10, 22.84, 23.48, 24.06, 24.36, 25.56 degrees in term of two theta; or an X-ray powder diffraction pattern comprising one or more peaks at about 7.48, 10.34, 10.82, 12.04, 13.10, 14.52, 15.52, 16.88, 17.52, 18.26, 19.00, 19.62, 20.54, 20.92, 21.38, 22.10, 22.84, 23.48, 24.06, 24.36, 25.56, 26.36 degrees in term of two theta; or an X-ray powder diffraction pattern substantially as depicted in Figure 16 wherein the peak at about 20.92 degree in term of two theta has a relative intensity of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 99% with respect to the strongest peak in the X-ray powder diffraction pattern.

14. A process for preparing the crystalline form of azilsartan medoxomil potassium of any one of claims 1-13, comprising dissolving azilsartan medoxomil in a solvent to form a solution; to the solution was added potassium salt, then forming crystals at a suitable temperature, wherein the solvent is one or more polar solvents, one or more non-polar solvents or a combination thereof, wherein the solvent is selected from dimethyl formamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, water, ether solvents, ketone solvents, ester solvents, aromatic hydrocarbon solvents, alkane

solvents, nitrile solvents and combinations thereof.

15. A process of claim 14, wherein the potassium salt is organic acid potassium salt or inorganic acid salt, comprising potassium nitrate, potassium sulfate, potassium sulfite, potassium bromate, potassium bicarbonate, potassium thiocyanate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium hydrogen phthalate, potassium acetate, Potassium formate, Potassium di-tert-butylphosphate, dipotassium glycyrrhizinate, Potassium 2-ethylhexanoate, potassium ethyl xanthate, potassium sorbate and combination thereof.

16. A process for preparing the crystalline form of azilsartan medoxomil potassium of any one of claims 1-13, comprising dissolving azilsartan medoxomil potassium in a solvent, then crystallization from the solvent, wherein the solvent is one or more polar solvents, one or more non-polar solvents or a combination thereof, wherein the solvent is selected from dimethyl formamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, water, ether solvents, ketone solvents, ester solvents, aromatic hydrocarbon solvents, alkane solvents, nitrile solvents and combinations thereof.

17. The process of any one of claims 14-16, wherein the ether solvents are selected from methyl-tetrahydrofuran, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, or methyl tert-butyl ether; wherein the ketone solvents are selected from acetone, methyl ethyl ketone, or 4 - methyl-2- pentanone; wherein the ester solvents are selected from ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, sec-butyl acetate, wherein the alkane solvents are selected from dichloromethane, 1,2-dichloroethane, chloroform, carbon tetrachloride, nitroethane, n-hexane, cyclohexane or n-pentane or n-heptane; wherein aromatic hydrocarbon solvents are selected from benzene , toluene or xylene; wherein nitrile solvents are selected from acetonitrile or malononitrile.

18. The process according to claim 17 for preparing crystalline form C of azilsartan medoxomil potassium in substantially pure, wherein the solvent is selected from propanone, 4 - methyl-2-pentanone, ethyl acetate, dichloromethane, dichloroethane, isobutyl acetate, sec-butyl acetate, methyl tetrahydrofuran, nitroethane, 1,2-dichloroethane, methyl ethyl ketone, dioxane, ethylene glycol dimethyl ether, acetonitrile, tetrahydrofuran, cyclohexane and combinations thereof.

19. A pharmaceutical composition comprising the crystalline form of azilsartan medoxomil potassium of any one of claims 1-13 and one or more of inert excipients or carriers.



20. The composition of claim 19, wherein the crystalline form of azilsartan medoxomil potassium is form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L and wherein the crystalline form of azilsartan medoxomil potassium is substantially pure.

21. The composition of claim 19, wherein the inert excipients or carriers are mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crosslinked cellulose, microcrystalline cellulose, magnesium stearate and combinations thereof.

22. The crystalline form of azilsartan medoxomil potassium of any one of claims 1-13

or the pharmaceutical composition of claim 19 for use in preventing or treating hypertension in a patient.

23. A method of preventing or treating hypertension in a patient by administering to the patient a pharmaceutically effective amount of the crystalline form of azilsartan medoxomil potassium of any one of claims 1-13 or the pharmaceutical composition of claim 19.

**Figure 1****Figure 2**




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11








Figure 12

**Figure 13****Figure 14****Figure 15****Figure 16**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2013/070427

A. CLASSIFICATION OF SUBJECT MATTER

See extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D413/10, A61K31/4245

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CNPAT, CNKI, WPI, EPODOC, REG, CAPLUS, azilsartan, medoxomil, potassium, crystal, oxadiazol?, benzimidazol?, biphenyl, angiotensin, hypertension, CAS RN:863031-21-4, 863031-24-7

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO2012090043A1 (JUBILANT LIFE SCI LTD), 05 Jul. 2012 (05.07.2012), see examples and claims	1-23
A	US20050187269A1 (TAKEDA PHARM CO LTD), 25 Aug. 2005 (25.08.2005), see example 5 and paragraph [0210]	1-23

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance

“E” earlier application or patent but published on or after the international filing date

“L” document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)

“O” document referring to an oral disclosure, use, exhibition or other means

“P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&” document member of the same patent family

Date of the actual completion of the international search

03 Apr. 2013 (03.04.2013)

Date of mailing of the international search report

25 Apr. 2013 (25.04.2013)

Name and mailing address of the ISA/CN

The State Intellectual Property Office, the P.R.China
6 Xitucheng Rd., Jimen Bridge, Haidian District, Beijing, China
100088
Facsimile No. 86-10-62019451

Authorized officer

YANG Yi

Telephone No. (86-10)62086352

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2013/070427

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 23

because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 23 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the crystalline forms (see Rule 39.1.(iv)).

2. ☐ Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CN2013/070427

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
WO2012090043A1	05.07.2012	None	
US20050187269A1	25.08.2005	CA2557538A	01.09.2005
		AU2005214271A	01.09.2005
		WO2005080384A	01.09.2005
		JP2005272451A	06.10.2005
		AR047972A	15.03.2006
		EP1718641A	08.11.2006
		NO332344B	03.09.2012
		US2006281795A	14.12.2006
		MA28478B	01.03.2007
		CN1946717A	11.04.2007
		BRPI0507984A	24.07.2007
		AT370136T	15.09.2007
		PT1718641E	15.11.2007
		EP1857457A	21.11.2007
		DK1718641T	17.12.2007
		SI1718641T	31.12.2007
		HRP20070510T	31.12.2007
		HK1098472A	01.02.2008
		ES2293552T	16.03.2008
		DE602005002030T	08.05.2008
		CN101381366A	11.03.2009
		NZ549755A	30.04.2009
		JP2009137974A	25.06.2009
		AT440095T	15.09.2009
		PT1857457E	23.09.2009
		RU2369608C	10.10.2009
		US2009270464A	29.10.2009
		EP2119715A	18.11.2009
		DK1857457T	21.12.2009

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CN2013/070427

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
		ES2331209T	23.12.2009
		SI1857457T	29.01.2010
		HRP20090593T	31.03.2010
		HK1115118A	23.04.2010
		RS50537B	07.05.2010
		RU2009115498A	27.10.2010
		RS51137B	31.10.2010
		IL177533A	30.12.2010
		MY142807A	14.01.2011
		TWI336702B	01.02.2011
		LU91962I	21.05.2012
		DE122012000018I	06.06.2012
		PT2119715E	03.09.2012
		DK2119715T	10.09.2012
		HRP20120667T	30.09.2012
		ES2388945T	22.10.2012
		SI2119715T	30.10.2012
		NO2012017I	26.11.2012
		RS52376B	31.12.2012

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2013/070427

A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both national classification and IPC

C07D413/10 (2006.01)i

A61K31/4245 (2006.01)i

A61P9/12 (2006.01)i